个人简历

硕博，日本名古屋大学（1985-1990年）
博士后，哈佛大学（哈佛大学校长特邀博士后研究员，1990-1993年）
1993年5月—1998年2月研究员，项目经理，Novartis，USA
1998年2月—2000年1月化学业务总监，RepliGen Co., Needam, USA
2000年1月—2002年6月高级研究员，项目经理；Cytokinetics, Inc., USA
2002年6月—2008年6月高级研究员，项目经理；Roche/Genentech, Inc., USA
2008年6月—现在董事长兼总经理；AlphaBiopharmaceuticals,Inc., USA
2011年1月—现在江南大学太湖学者，特聘教授。工作期间，
在美国工作期间，有10个新药候选物进入欧美等国的临床研究； 取得临床批件40余张； 有4个新药上市（Tobi，Vismodegib，Kadcyla，TOBI Podhaler），
25年丰富且成功的新药物研发经验，拥有15项美国新药研发发明专利。
先后获批江苏省“双创”高端引进人才（2011年）；无锡市领军人物（2012年）

研究领域

天然物化学，心血管疾病药物、抗感染药物、抗炎症药物，智能抗糖尿病药物，免疫性疾病以及抗肿瘤靶向药物

近期论文

1. Determination of an isonicotinylhydrazide derivative, a novel positive inotropic compound, in mouse plasma by LC-MS/MS and its application to a pharmacokinetics studyJournal of Pharmaceutical and Biomedical Analysis (2019), 165, 12-17.
2. Design, synthesis, and biological evaluation of 2-(4-(methylsulfonyl)phenyl)pyridine derivatives as GPR119 agonistsChemical Biology & Drug Design (2019), 93(1), 67-74.
3. Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitorsBioorganic & Medicinal Chemistry Letters (2018), 28(20), 3385-3390.
4. Alkylation method of nitrogen-containing hydrogen compound and its applicationFaming Zhuanli Shenqing (2018), CN 108503583 A 20180907,
5. Preparation of pyrazolo[1,5-a]pyrimidine compounds as antitumor agentsFaming Zhuanli Shenqing (2018), CN 108484613 A 20180904,
6. Pyrimido[4,5-f]quinazoline compounds as CDK inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancerFaming Zhuanli Shenqing (2018), CN 108484606 A 20180904,
7. Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitorsEuropean Journal of Medicinal Chemistry (2018), 157, 935-945.
8. Pyrazolo[4,3-h]quinazoline compound and application thereofFaming Zhuanli Shenqing (2017), CN 107383019 A 20171124,
9. A polypeptide derivatization method and its application in maldi-tof-ms detection of medicine metabolites [Machine Translation].Faming Zhuanli Shenqing (2017), CN 107085032 A 20170822,
10. Transition-Metal-Free Trifluoromethylation of Aldehyde Derivatives with Sodium TrifluoromethanesulfinateJournal of Organic Chemistry (2017), 82(18), 9384-9399.
11. 1,2,5-Thiadiazole-2-oxide analogues as schistosomicides and their preparation, pharmaceutical compositions and use in the treatment of schistosomiasisFaming Zhuanli Shenqing (2017), CN 106632142 A 20170510,
12. Method for preparing statin bulk drug intermediate with improved Julia olefination reaction as key stepFaming Zhuanli Shenqing (2017), CN 106588763 A 20170426,
13. Synthesis method for chiral secondary allyl alcohol with hydroxy ortho position substituted with halogen atomFaming Zhuanli Shenqing (2017), CN 106588565 A 20170426,
14. Development and validation of pharmacophore of G protein-coupled receptor 40 agonistsJisuanji Yu Yingyong Huaxue (2017), 34(2), 157-162.
15. Gold-Oxazoline Complex-Catalyzed Cross-Dehydrogenative Coupling of Glycine Derivatives and AlkenesAdvanced Synthesis & Catalysis (2017), 359(5), 824-831.
16. Synthesis of aromatic amide derivatives and their biological evaluation against protein tyrosine phosphatase 1B and protein tyrosine phosphatase SHP2Youji Huaxue (2016), 36(9), 2142-2149.
17. Oxadiazole-2-oxides may have other functional targets, in addition to SjTGR, through which they cause mortality in Schistosoma japonicumParasites & Vectors (2016), 9, 26/1-26/12.
18. Lead-removing polysulfide ether composition and its application in health foodFaming Zhuanli Shenqing (2016), CN 105815781 A 20160803,
19. A sugar protein fluorescent probe molecules for continuous synthesis methodFaming Zhuanli Shenqing (2016), CN 105806820 A 20160727,
20. Gene expression profiling of H9c2 cells subjected to H2O2-induced apoptosis with/without AF-HF001Biological & Pharmaceutical Bulletin (2016), 39(2), 207-214.